Menu
The high prevalence of blood cancers globally1 has resulted in an increasing recognition of the diversity among hematological malignancies. Specialists are now encouraged to classify disease by genomic mutations2, which can add complexity, delays and cost to testing and result interpretation.
Use one universal, automated protocol for robust sequencing across applications.
Analyze SNVs, Indels, CNVs, ITDs, PTDs, and gene fusions, with confidence.
Match blood cancer genomic profiles to the most up-to date information with OncoPortal™ Knowledge Base.
Quickly prepare comprehensive reports adapted to your needs.
Precise molecular barcoding
Sensitive SNV and Indel detection
Accurate CNV calling
Partner-agnostic fusion detection
Robust variant annotation
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
